Ferguson Toby 4

What Happened
Toby Ferguson, Chief Medical Officer of Voyager Therapeutics, received two compensation grants on February 6, 2026: 45,000 restricted stock units (RSUs) and a stock option covering 210,000 shares. Both items were reported as acquisitions (Code A) at $0.00 — these are grants, not purchases or option exercises, so no cash changed hands at grant.

Key Details

• Transaction date: February 6, 2026; Form 4 filed February 10, 2026 (timely filed).
• Grants: 45,000 RSUs (acquisition at $0.00) and a derivative award of 210,000 stock options (acquisition at $0.00).
• Vesting for RSUs: Commencement date Feb 6, 2026; vests over 3 years, with 1/3 vesting each year subject to continued service.
• Vesting for option: Commencement date Feb 6, 2026; vests over 4 years with 1/48th vesting after one month and then monthly thereafter (subject to continued service).
• Shares owned after the transaction: Not specified in the provided filing excerpt.
• Footnotes: F1 describes the 45,000 RSUs and their 3-year annual vesting schedule; F2 describes the stock option and its 4-year monthly vesting schedule.
• Filing timeliness: Filed Feb 10, 2026 for a Feb 6 transaction — within the standard Form 4 reporting window.

Context These grants are standard equity compensation for an executive and do not represent a sale or a cash purchase. The option is a grant (not an exercise) and will only have value if Voyager’s stock price exceeds the option’s exercise price when/if exercised; the filing does not disclose an exercise price or immediate sale of shares. Such awards are routine for employee compensation and do not by themselves indicate insider buying or selling sentiment.